Alex Sapir is the founder of ReViral. ReViral has raised $154M in total funding. Latest round: IPO. Based in UK.
Alex Sapir serves as the CEO of ReViral, a UK-based clinical-stage biotechnology company focused on developing antiviral compounds for respiratory syncytial virus (RSV). Before joining ReViral, he held leadership positions at Dova Pharmaceuticals and was the Chief Executive at Fulcrum Therapeutics.
Full founder directory · Investor directory · Company funding database · Fundraising library